Ambrisentan

It is an orally active, highly selective antagonist of the ET-1 type A receptor, is indicated for the treatment of PAH.

Indications

Pulmonary artery hypertension

Dosage

Oral; 5-10mg once daily.

Contra-Indications

Hepatic impairement, Hypersensitivity.

Special Precautions

Paediatric : safety not established Pregnancy: category X, contraindicated Lactation: Not known wheather excreted in milk. Breastfeeding while receiving ambrisentan is not recommended. Elderly: safe

Side Effects

Vomiting, Right ventricular failure, pulmonary hypertension, acute respiratory failure, cardiac arrest, cardiorespiratory arrest, pneumonia, diarrhea, Hemorrhage, Intracranial, Hepatic enzyme increased, Hypoxia, Pyrexia, Respiratory arrest, sudden death, syncope.

Drug Interactions

cyclosporine, Digoxin, sildenafil, warfarin, ethinylestradiol, norethindrone.